跳至主要内容
临床试验/CTRI/2021/05/033337
CTRI/2021/05/033337尚未招募3 期

Effect of stopping nucleos(t)ide therapy in non-cirrhotic chronic hepatitis B patients on hepatitis B surface antigen clearance- open-label pilot randomized control trial - STOPHEP

Dr Shalimar0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Non-cirrhotic chronic hepatitis B infected patients who are on nucleotide analogue therapy with undetectable HBV DNA for the last 3 years
  • 2.Age between 18-65 years
  • 3.Willing to participate

排除标准

  • 1. Presence of cirrhosis or significant fibrosis (LSM > 8 kPa)
  • 2. Decompensated cirrhosis
  • 3. Pregnant women
  • 4. Co-infection with hepatitis C virus or HIV
  • 5. Hepatocellular carcinoma
  • 6. Detectable DNA in last 3 years
  • 7. Immunocompromised status requiring continuous nucleotide treatment
  • 8. Non compliant to medication in 3 years

研究者

发起方
Dr Shalimar

相似试验

A trial to assess the effect of stopping antiviral... | 临床试验